Tuesday, April 3, 2012

Postcard From the AACR 2012 Annual Meeting - Part 1

Annual Meeting of the American Association for Cancer Research (AACR) is ongoing right now in the city of Al Capone.  And 17,000 cancer biologists, oncologists and just about anyone interested in the cancer research have taken over the Chicago downtown which means that there is a tsunami of oncology-related information and much to learn.  


Here is what has bubbled to the top and comes through the much-appreciated efforts of a handful of people who have shared this distilled knowledge via twitter.  These include Pieter Droppert @NT, Naoto T. Ueno @teamoncology, @JNCI_Now,  Scott Merville‏ @smerv  David Woessner‏ @pinfoto Kenna Shaw‏ @wyattsgirl, and others.
The meeting summary is summarized here in four parts:




Part 1 (this post): 
  • Various cancers (lung, prostate, breast, ovarian, cervical liver, stomach, pancreatic, melanoma, skin, head and neck, urothelial, brain cancers and gliomas, lymphomas and leukemias.)
  • Drugs and strategies targeting cell metabolism, epigenetics, angiogenesis and microenvironment, p53, PI3K.
  • Tackling resistance and managing Stage IV disease
  • Cancer models
Part 2 (next post):
  • Funding situation, 
  • Clinical trials' issues, patients' concerns
  • Epidemiology, prevention


Part 3 (following post):
  • Mechanisms of cancer
  • NGS; TCGA project


Part 4 (accompanying post):
  • The quotes
  • The grapevine
  • and what else!






LUNG CANCER


Drugs, Trials
  • #AACR #SU2C Dream Team tests demethylating agent in lung cancer clin trial. Epi + subsequent therapy 21 % patients respond. 54% stable. --  Scott Merville‏ @smerv  11:47 AM - 1 Apr 12 via web • Tweet
  • Combined rexinois and triterpenoids show synergistic activity at reduced doses in pre-clinical lung cancer model. Same in SAHA combo. #AACR. --  David Woessner‏ @pinfoto  11:20 AM - 2 Apr 12 via Echofon •  Tweet
  • Myo-inositol (PI3K inhibitor) can reverse gene expression signature predictive of lung cancer development in small phase I study. #AACR. --  David Woessner‏ @pinfoto  11:48 AM - 2 Apr 12 via Echofon •  Tweet
Biomarkers
  • Now up: biomarker for targeted prevention of lung cancer using airway cells - Avrum E. Spira, Boston University #AACR.  --  David Woessner‏ @pinfoto  11:40 AM - 2 Apr 12 via Echofon • Tweet
Diagnosis



  • Low dose ct seems better than chest xray for the detection of earlier lung cancers and death rates but not everyone can pay for it #aacr. -- A6raham And3rs0n‏ @tpolytmus 11:56 AM - 1 Apr 12 via TweetDeckTweet






PROSTATE CANCER


SU2C prostate cancer dream team



  • #AACR: Stand Up 2 Cancer announces prostate cancer dream team: focus on adv disease; will create "Precision Tumor Boards" to chart mutations. -- J Nat'l Cancer Inst‏ @JNCI_Now 1:14 PM - 1 Apr 12 via webTweet
  • #AACR: Researchers on prostate cancer dream team hope adv prostate cancer will be model for precision medicine in modeling tumor types. -- J Nat'l Cancer Inst‏ @JNCI_Now 1:16 PM - 1 Apr 12 via webTweet
  • #AACR Charles Sawyers says "this is the tipping point for prostate cancer" referring to new Stand up to Cancer dream team. -- Medscape‏ @Medscape 12:09 PM - 1 Apr 12 via bitly •  Tweet 

 Drugs, Trials
  • Next up in new drugs session: Paul Polakis from Genentech on targeting prostate cancer with anti-STEAP1 antibody-drug conjugate #aacr. -- Pieter Droppert‏ @3NT 2:11 PM - 1 Apr 12 via Echofon • Tweet 
  • Naked monoclonal antibodies are deemed overrated. Time for ADCs. Paul Polakis presenting an ADC against Steap1 in prostate cancer #AACR. -- Philippe Aftimos MD‏ @aftimosp 2:19 PM - 1 Apr 12 via Twitter for iPad Tweet
  • Polakis: developed monoclonal antibodies to Steap1 in collaboration with Agensys (Astellas Pharma) #aacr. -- Pieter Droppert‏ @3NT 2:18 PM - 1 Apr 12 via Echofon Tweet
  • Polakis: Steap1 expressed in prostate cancer #aacr. -- Pieter Droppert‏ @3NT 2:16 PM - 1 Apr 12 via Echofon Tweet 
  • Only presented animal data for anti-STEAP-1 ADC so interesting to see human safety & efficacy data in due course #aacr. -- Pieter Droppert‏ @3NT 2:38 PM - 1 Apr 12 via Echofon • Tweet 
  • Re ThioMab & antiSTEAP-1 from #AACR I just added stability effect on PK study to my reading list http://www.ncbi.nlm.nih.gov/pubmed/21913715-- Laura Strong‏ @scientre 4:30 PM - 1 Apr 12 via Twitter for iPad • Tweet
  • Zirconium anti-steap1 molecular imaging! #AACR. -- Philippe Aftimos MD‏ @aftimosp 2:21 PM - 1 Apr 12 via Twitter for iPad • Tweet


  • Loddick: selective AR down-regulation SARD inhibits CRPC in vivo #aacr. -- Pieter Droppert‏ @3NT 2:04 PM - 1 Apr 12 via Echofon • Tweet 
  • Loddick: AZD3514 inhibits AR nuclear translocation, has a dose-dependent effect on AR protein expression in vivo #aacr. -- Pieter Droppert‏ @3NT 2:03 PM - 1 Apr 12 via Echofon • Tweet 
  • Loddick: AZD3514 reduces rate of AR synthesis & inhibits AR activity before AR down-regulation is observed #aacr. -- Peter Droppert‏ @3NT 1:54 PM - 1 Apr 12 via Echofon • Tweet 
  • Loddick: AZD3514 is in multi-center phase 1 trial in patients with metastatic CRPC #aacr. -- Pieter Droppert‏ @3NT 2:07 PM - 1 Apr 12 via Echofon • Tweet 
  • Loddick: AZD3514 inhibits prostate tumor growth in vivo #aacr. -- Pieter Droppert‏ @3NT 2:01 PM - 1 Apr 12 via EchofonTweet 
  • Loddick: inhibition of AR signaling inhibits seminal vesicle growth in adolescent rats #aacr. -- Pieter Droppert‏ @3NT 1:59 PM - 1 Apr 12 via EchofonTweet 
  • Loddick: discussing potential mechanisms by which AZD3514 induces AR down-regulation #aacr. -- Pieter Droppert‏ @3NT 1:53 PM - 1 Apr 12 via EchofonTweet 
  • Loddick: AR signaling is maintained in CRPC - multiple potential mechanisms for reactivation of AR signaling in CRPC #aacr. -- Pieter Droppert‏ @3NT 1:48 PM - 1 Apr 12 via Echofon • Tweet 
  • Loddick: AZD3514 is a selective AR down-regulator (SARD) - a novel mechanism to inhibit AR signaling#aacr. -- Pieter Droppert‏ @3NT 1:50 PM - 1 Apr 12 via EchofonTweet 
  • AZD3514 looks to be an interesting new prostate cancer drug to watch #aacr. -- Pieter Droppert‏ @3NT 2:08 PM - 1 Apr 12 via Echofon •  Tweet  (RESPONSE TO ABOVE) Jason Chew ‏ @JasonCRG @3NT does any other drug work like this? seems novel AZD3514
  • Next up in new drugs on horizon: Sarah Loddick from AstraZeneca on AZD3514 & it's potential in CRPC #aacr. -- Pieter Droppert‏ @3NT 1:45 PM - 1 Apr 12 via EchofonTweet 





  • #Galeterone, a new drug being tested for#prostatecancer, may treat those no longer responsive to hormone therapy #AACR. -- BMC Medicine‏ @BMCMedicine Tweet 
  • In @UWMedicineNews, early clinical data show galeterone safe, effective against #prostate #cancer http://j.mp/H9wiwH #aacr 2012. -- NCI Media Relations‏ @NCIMedia 2:51 PM - 2 Apr 12 via TweetDeckTweet
  • PSA Drop Seen with New #ProstateCancer Drug#AACR http://bit.ly/Hy62Bx. -- MedPage Today‏ @medpagetoday 10:01 AM - 2 Apr 12 via Sprout SocialTweet





  • #AACR Neoadjuvant metformin may slow the progression of prostate cancer, according to early data http://ff.im/-TTBsL. -- McGeneral‏ @gbmiii 11:48 AM - 1 Apr 12 via FriendFeed Tweet
  • $BPAX trotting back out the same prostate cancer GVAX + ipi trial at #AACR http://www.biotechduediligence.com/1/post/2012/04/biosante-pharma-bpax-cancer-vaccine-data-at-aacr.html-- Andrew Goodwin‏ @BioDueDiligence 5:18 PM - 1 Apr 12 via web • Tweet
  • @PCFnews funded scientist James Allison talks immunotherapy at #AACR opening session to 17,000 scientists & researchers http://pic.twitter.com/9Alwkh2W. -- Prostate Cancer Fdn‏ @PCFnews powered by   Photobucket 6:05 PM - 1 Apr 12 via web  Tweet 





BREAST CANCER


.
.
.


OVARIAN CANCER


Epidemiology
  • Ovarian cancers will strike approximately 2.2 million of the women in the U.S. alive today.#AACR. -- J Nat'l Cancer Inst‏ @JNCI_Now 9:24 AM - 2 Apr 12 via webTweet
Drugs, Trials
  • #AACR Small-molecule MEK inhibitor selumetinib appears to control low-grade serous ovarian/peritoneal cancer. -- Medscape‏ @Medscape 11:51 AM - 1 Apr 12 via bitlyTweet


CERVICAL CANCER


Epidemiology





  • Black women have more trouble cleaning HPV. High risk for cervical cancer. #AACR http://fb.me/VxcoxpcX. -- Naoto T. Ueno 上野直人‏ @teamoncology 6:42 AM - 2 Apr 12 via FacebookTweet
  • Study at #AACR (Creek) suggests Black women don't clear HPV as well. If confirmed, may mean vaccine is even more important in this group. -- ‏ @jpil 6:47 PM - 1 Apr 12 via TweetDeck Tweet 
  • RT @mundosalud @JNCI_Now: #AACR: #HPV causes 5% of human cancers in world; 10% of cancers in women;15-25% in women in developing countries. -- Michael Fisch‏ @fischmd 4:02 PM - 1 Apr 12 via HootSuiteTweet 
  • #AACR Black women clear HPV much slower than white women, indicating a biological basis for higher rates of cervical cancer. -- Medscape‏ @Medscape 11:42 AM - 1 Apr 12 via bitlyTweet


LIVER CANCER

Epidemiology
  • Liver cancer is the third most common cause of cancer-related deaths. #AACR. -- J Nat'l Cancer Inst‏ @JNCI_Now 12:44 PM - 2 Apr 12 via web Tweet
  • #AACR: hepatocellular carcinoma 2nd cuase of cancer-related death in world; Hepatitis C virus infection major cause in West. -- J Nat'l Cancer Inst‏ @JNCI_Now 6:52 AM - 2 Apr 12 via webTweet
  • 【#AACR 101】 Liver cancer is very common in Asia. Big health issue. -- Naoto T. Ueno 上野直人‏ @teamoncology 7:10 AM - 2 Apr 12 via Twitterrific for MacTweet
Drugs, Trials
  • #AACR Tremelimumab Shows Promise in Treatment of Liver Cancer: http://bit.ly/HGVObLvia @AACR. -- Scott Merville‏ @smerv 2:25 PM - 2 Apr 12 via Tweet ButtonTweet
  • #AACR: Ph II trial of monoclonal antibody tremelimumab in advanced HCC patients is safe, has antiviral effect in more than 50% of patients. -- J Nat'l Cancer Inst‏ @JNCI_Now 6:54 AM - 2 Apr 12 via web • Tweet
  • #AACR Preliminary data shows tremelimumab has promising antitumor efficacy against HCC and an intense antiviral activity against HCV. -- Medscape‏ @Medscape 10:50 AM - 2 Apr 12 via bitly Tweet
  • Tremelimumab Shows Promise in Treatment of#Liver Cancer http://ow.ly/a1QqT - News from#AACR. -- Stefanie Greene‏ @StefanieAACR 11:40 AM - 2 Apr 12 via HootSuiteTweet
  • 【#AACR 101】 Tremelimumab is a monoclonal antibody that targets CTLA-4. It enhances immune system to fight cancer. From Pfizer. -- Naoto T. Ueno 上野直人‏ @teamoncology 7:14 AM - 2 Apr 12 via Twitterrific for MacTweet
  • #GlaxoSmithKline's #GSK2636771 shows efficacy in hepatocellular carcinoma cell lines. Live from#AACR.  -- Cortellis Editorial‏ @Cortellis 6:25 PM - 1 Apr 12 via web • Tweet
Diagnosis, etc
  • Ability to monitor CTC levels in a liver cancer patient's blood improves clinician's ability to gauge effectiveness of drug therapies. #AACR.  -- J Nat'l Cancer Inst‏ @JNCI_Now 12:47 PM - 2 Apr 12 via webTweet



STOMACH CANCER
  • #AACR title: a tale of two stomachs. --  Brendan Maher‏ @bmahersciwriter 9:35 AM - 2 Apr 12 via Echofon • Tweet
Etiology
  • #AACR Martin Blaser is talking about the tense relationship between the stomach and H. Pylori. Causing cancer and sometimes preventing. --  Brendan Maher‏ @bmahersciwriter 9:35 AM - 2 Apr 12 via Echofon • Embed this Tweet


PANCREATIC CANCER

Epidemiology

  • Pancreatic cancers will strike approximately 4.5 million men & women in the U.S. alive today.#AACR. -- J Nat'l Cancer Inst‏ @JNCI_Now 9:23 AM - 2 Apr 12 via web • Tweet

Drugs, Trials



MELANOMA, SKIN CANCERS

Epidemiology
  • Alarming trends of increasing melanoma in US women assoc. w/ indoor tanning bed usage.#AACR. -- J Nat'l Cancer Inst‏ @JNCI_Now 10:12 AM - 2 Apr 12 via web • Tweet
Drugs, Trials
  • Monoclonal antibody ipilimumab may have activity in melanoma patients with brain metastases.#AACR http://fb.me/YaZBphu2 . -- Naoto T. Ueno 上野直人‏ @teamoncology 6:44 AM - 2 Apr 12 via FacebookTweet

HEAD AND NECK CANCER


Drugs, Trials
  • HER3/EGFR dual action antibody MEHD7945A phase 1 trial shows initial activity in head & neck cancer #AACR. -- Pieter Droppert‏ @3NT 3:06 PM - 2 Apr 12 via EchofonTweet
  • First in human phase I study of #Genentech#MEHD-7945A at #AACR 2012. -- Cortellis Editorial‏ @Cortellis 2:50 PM - 2 Apr 12 via Twitter for BlackBerry® Tweet




UROTHELIAL CANCER


Drugs, Trials
  • Antiangiogenic Pazopanib Active in Refractory Urothelial Cancer, #AACR http://www.medpagetoday.com/article.cfm?tbid=31965#.T3miQ28VdEA.twitter . -- PDara MD, FACP‏ @JediPD 5:58 AM - 2 Apr 12 via Tweet Button Tweet



BRAIN CANCERS, GLIOMAS

Epidemiology

  • The 5-year relative survival for brain cancers diagnosed from 2001 through 2007 was 34.8%.#AACR. -- J Nat'l Cancer Inst‏ @JNCI_Now3:21 PM - 2 Apr 12 via Twitter for iPhone • Tweet

Drugs, Trials

  • #AACR: Pilot study of peptide-based vaccine for high-risk gliomas in children is well tolerated; needs further analyses. -- J Nat'l Cancer Inst‏ @JNCI_Now 6:57 AM - 2 Apr 12 via web Tweet
  • #AACR Peptide vaccines in children with gliomas is well tolerated & preliminary evidence shows immunological and clinical activity. -- Medscape‏ @Medscape 10:42 AM - 2 Apr 12 via bitly • Tweet
  • #AACR folks: interesting peptide vaccine report in kids w/gliomas but what's rationale for survivin epitopes? http://www.newswise.com/articles/view/587438/ . -- David Kroll‏ @davidkroll 11:13 AM - 2 Apr 12 via Echofon Tweet
  • PITT study of peptide vaccine shows evidence of immunological response in #children with#gliomas http://j.mp/HbcAmn #cancer #AACR2012. -- NCI Media Relations‏ @NCIMedia 3:25 PM - 2 Apr 12 via TweetDeckTweet
  • #AACR DelMar's new data generating broad and deep interest. #genomics VAL-083 is sort of a specific, non-specific agent for GBM, other CAs. -- Bill Garner, MD‏ @innovationMD 6:54 AM - 2 Apr 12 via Twitter for iPad • Tweet



LYMPHOMAS, LEUKEMIAS

Drugs, Trials
  • Sebastian Schwind discusses AML combination therapy with bortezomib (FLT3 down regulation) with decitibine.- phase I study #AACR. -- David Woessner‏ @pinfoto 1:49 PM - 2 Apr 12 via EchofonTweet
  • Bortezomib downregulates FLT3 expression via NFkB in pre-clinical models, and in PhI trials. FLT3 mutants in about 30% of AML cases. #AACR. -- David Woessner‏ @pinfoto 2:03 PM - 2 Apr 12 via EchofonTweet
  • Ph 1 data: Bortezomib plus Decitabine is reasonably well tolerated in poor risk AML pts: may be new approach to target FLT3 #aacr. -- Pieter Droppert‏ @3NT 2:12 PM - 2 Apr 12 via Echofon Tweet
  • Researchers at @theNCI find investigational targeted drug induces responses in aggressive#lymphomas http://j.mp/HffUy7 #cancer #aacr. -- NCI Media Relations‏ @NCIMedia 8:09 AM - 2 Apr 12 via TweetDeck Tweet

  • Steven Elmore from Abbott to discuss ABT-199 at#aacr-- Pieter Droppert‏ @3NT 1:18 PM - 1 Apr 12 via Echofon • Tweet  
  • ABT-199 phase 1 data looks promising in CLL - data to be presented at EHA in June #aacr. -- Pieter Droppert‏ @3NT 1:42 PM - 1 Apr 12 via Echofon.  Tweet
  • Elmore: a single-dose of ABT-199 can achieve rapid reduction of CLL burden in patients with refractory disease - data at EHA 2012 #aacr. -- Pieter Droppert‏ @3NT 1:41 PM - 1 Apr 12 via Echofon Tweet
  • Impressive! Activity of ABT-199 in first cohort of phase 1 trial #AACR. -- Philippe Aftimos MD‏ @aftimosp 1:40 PM - 1 Apr 12 via Twitter for iPadTweet
  • Synergy of ABT-199 also demonstrated with cobination[sic] chemotherapy #AACR. -- Philippe Aftimos MD‏ @aftimosp 1:39 PM - 1 Apr 12 via Twitter for iPad Tweet
  • Elmore: ABT-199 enhances the efficacy of standard treatment regimens in murine xenograft models of NHL #aacr. -- Pieter Droppert‏ @3NT 1:39 PM - 1 Apr 12 via EchofonTweet
  • Synergy of the Bcl-2 inhibitor ABT-199 with rituximab in DLBCL #AACR. -- Philippe Aftimos MD‏ @aftimosp 1:38 PM - 1 Apr 12 via Twitter for iPadTweet
  • Elmore: showing animal data that ABT-199 is platelet sparing #aacr. -- Pieter Droppert‏ @3NT 1:32 PM - 1 Apr 12 via Echofon Tweet
  • Elmore: ABT-199 has high affinity for Bcl-2, lower affinity for Bcl- xl #aacr. -- Pieter Droppert‏ @3NT 1:29 PM - 1 Apr 12 via Echofon Tweet
  • Elmore: ALL cell lines are 'primed for death' - ABT-199 induces tumor regression #aacr. -- Pieter Droppert‏ @3NT 1:34 PM - 1 Apr 12 via Echofon Tweet
  • Elmore: Bcl-2 family proteins regulate intrinsic apoptosis #aacr. -- Pieter Droppert‏ @3NT 1:22 PM - 1 Apr 12 via Echofon Tweet
  • Elmore: Bcl-2 is first identified regulator of apoptosis #aacr. -- Pieter Droppert‏ @3NT 1:21 PM - 1 Apr 12 via Echofon Tweet
  • Elmore: reverse engineering leads to Bcl-2 selectivity, design cues from x-ray crystal artifact#aacr. -- Pieter Droppert‏ @3NT 1:26 PM - 1 Apr 12 via Echofon · Tweet 



There is a bcl-2 related protein called "bad". That can't be good... #AACR. -- Philippe Aftimos MD‏ @aftimosp 1:25 PM - 1 Apr 12 via Twitter for iPad · Tweet


  • Elmore: Navitoclax inhibition profile dictates efficacy/toxicity - but platlet survival dependent on Bcl-xl #aacr. -- Pieter Droppert‏ @3NT 1:25 PM - 1 Apr 12 via Echofon · Tweet 
Genentech's Navitoclax targets bcl-2 family of anti-apoptotic proteins
  • #AACR: Issa notes SGI-110 has major response in patients with no options left; 1AML patient w recurrent disease in remission after 8 months. -- J Nat'l Cancer Inst‏ @JNCI_Now 1:11 PM - 1 Apr 12 via web Tweet
  • SGI-110 for acute myeloid leukemia patient achieved CR. Stem cell tplant had failed. CR 8 mos. out. #AACR #SU2C. -- Scott Merville‏ @smerv 12:05 PM - 1 Apr 12 via web Tweet
  • SGI-110 new drug has longer half life than currently available demethylating drugs. Better for solid tumors. #AACR #SU2C. -- Scott Merville‏ @smerv 12:01 PM - 1 Apr 12 via web Tweet
  • Issa: Does world need another DNA methylation inhibitor? 2 approved. New one by Astex appeared better. #AACR #SU2C. -- Scott Merville‏ @smerv 11:59 AM - 1 Apr 12 via webTweet


  • #AACR Investigational BTK inhibitor ibrutinib can induce clinically significant responses in aggressive lymphomas. -- Medscape‏ @Medscape 12:16 PM - 1 Apr 12 via bitly • Embed this Tweet 
  • The race is now on to identify mechanisms of probably upcoming resistance to BTK inhibitor ibrutinib #AACR. -- @ElementoLab 1:55 PM - 1 Apr 12 via webTweet


  • New epigenetic drug may help myelodysplastic synd (preleukemia) & leukemia. #AACR http://fb.me/1K8c3xALk . -- Naoto T. Ueno 上野直人‏ @teamoncology 12:27 PM - 1 Apr 12 via Facebook • Tweet 


TARGETING CANCER METABOLISM, CANCER STEM CELLS, EMT

  • Cancer metabolism session at #AACR: flux analysis in intact cells is key. -- NatureReviewsCancer‏ @NatureRevCancer • Tweet
  • RT @NatureRevCancer: A bit belated, but other take home message from #AACR cancer metabolism session is serine, serine, serine-- Anas Younes, M.D.‏ @DrAnasYounes 2:49 PM - 1 Apr 12 via Echofon • Tweet
  • #AACR: IDH1 mutations found in many tumor types; 1/3 of breast cancers have PIK3 mutations. -- J Nat'l Cancer Inst‏ @JNCI_Now 2:41 PM - 2 Apr 12 via web • Tweet

  • And also see our Web Focus on cancer metabolism joint with Nature: http://ow.ly/a0I5W
     #AACR . -- NatureReviewsCancer‏ @NatureRevCancer  • Tweet 
  • Surprised...it seems as though $MYRX went so far as to withdraw their #AACR poster #1928 re NAMPT cancer metabolism program-- Andrew Goodwin‏ @BioDueDiligence 5:16 PM - 1 Apr 12 via web • Tweet
Cancer stem cells
  • Hans Clevers (Lgr5 stem cells in self-renewal and cancer) has some pretty awesome videos in his plenary presentation. #AACR. -- Carole Tactacan‏ @carole12 7:52 AM - 2 Apr 12 via Tweetbot for iOS Tweet
  • Cancer Stem Cell Vaccine in Development Shows Antitumor Effect http://bit.ly/HGP3fr #AACR#cancerSC. -- Jim Till‏ @jimtill 12:49 PM - 2 Apr 12 via web Tweet
EMT
  • ADC speaker anti5T4 putative tumor initating cell marker (Damelin 2011 Cancer Research for basic data). Mentions 5T4 involved in EMT #AACR. -- Laura Strong‏ @scientre 11:39 AM - 1 Apr 12 via Twitter for iPadTweet
  • #OSI Pharmaceuticals' #OSI296 demonstrates efficacy in several xenograft cancer models. Live from #AACR. -- Cortellis Editorial‏ @Cortellis 9:59 PM - 2 Apr 12 via webTweet
> OSI296 is a tyrosine kinase inhibitor that block EMT
  • Tyler Jacks showed how Ko of nkx2.1 reverts murine lung cancer to something resembling gut.#aacr. -- A6raham And3rs0n‏ @tpolytmus 2:15 PM - 1 Apr 12 via TweetDeck • Tweet 

TARGETING EPIGENETICS
  • RT @fbiemar: QOTD: epigenetic therapy is "diplomacy" in the war on cancer. @SU2C #AACRPress Conference. -- Sherif Morgan‏ @DrSherifMorgan 12:10 PM - 1 Apr 12 via TweetCaster for Android • Tweet 
  • @ChronSciGuy #AACR annual meeting, Jean-Pierre Issa slides include your story on epigenetic drugs. Diplomacy vs. war on cancer cells. -- Scott Merville‏ @smerv 12:18 PM - 1 Apr 12 via web • Tweet

  • #AACR #SU2C Jean-Pierre Issa of Temple: Epigenetics -- software/instruction book for genes. Cancer epigenetics are reversible. -- Scott Merville‏ @smerv 11:54 AM - 1 Apr 12 via web Tweet
  • Baylin says that treatment with low dose methylation inhibitors upregulates the "immune response" and this may help fight the cancer#AACR. -- Raymond DuBois‏ @Rndubois 11:53 AM - 1 Apr 12 via Twitterrific Tweet
  • #AACR #SU2C Steve Baylin of Johns Hopkins on epigenetics. Demethylating agents approved for MDS but not for solid tumors. -- Scott Merville‏ @smerv 11:44 AM - 1 Apr 12 via web Tweet




  • #AACR:Stand Up 2 Cancer grant leads to research on SGI-110, a DNA methylation inhibitor that demonstrates improved efficacy, longer exposure-- J Nat'l Cancer Inst‏ @JNCI_Now 1:07 PM - 1 Apr 12 via web • Tweet
  • #AACR: SGI-110 shows longer half-life than current drugs; worth testing in solid tumors, said Jean-Pierre Issa, M.D. -- J Nat'l Cancer Inst‏ @JNCI_Now 1:09 PM - 1 Apr 12 via web • Tweet
  • RT @smerv: SGI-110 for acute myeloid leukemia patient achieved CR. Stem cell tplant had failed. CR 8 mos. out. #AACR #SU2C. -- Harold Hopkins‏ @hoppy212ny 12:10 PM - 1 Apr 12 via Seesmic • Tweet
  • RT @smerv: SGI-110 new drug has longer half life than currently available demethylating drugs. Better for solid tumors. #AACR #SU2C. -- Anas Younes, M.D.‏ @DrAnasYounes  • Tweet  
  • Really liked the session on chromatin and the epigenome as drug targets today at the #AACRmeeting. Great talk on the inhibitors of DOT1L. -- Eric di Luccio‏ @ericdiluccio 4:05 PM - 1 Apr 12 via Twitter for Mac • Tweet  


  • RT @smerv: Issa: Does world need another DNA methylation inhibitor? 2 approved. New one by Astex appeared better. #AACR #SU2C. -- Anas Younes, M.D.‏ @DrAnasYounes 12:21 PM - 1 Apr 12 via Echofon • Tweet 
  • New epigenetic drug may help myelodysplastic synd (preleukemia) & leukemia. #AACR http://fb.me/1K8c3xALk . -- Naoto T. Ueno 上野直人‏ @teamoncology 12:27 PM - 1 Apr 12 via Facebook • Tweet

TARGETING ANGIOGENESIS AND MICROENVIRONMENT

*Antiangiogenic drugs work by pruning abnormal neovasculature in the tumors, and as a result the overall vasculature is "normalized." This may result in better delivery of chemotherapy to the tumors.

Anti-angeniogenesis drugs, mechanisms
  • 【#AACR 101】 Angiogenesis: formation of new abnormal blood vessels to facilitate tumor growth. For example, Avastin can target this process. -- Naoto T. Ueno 上野直人‏ @teamoncology 6:46 AM - 2 Apr 12 via Twitterrific for Mac • Tweet
  • Jain: better survival for patients with normalization of vasculature and so increased blood flow with anti-angiogenic therapy #AACR. -- Philippe Aftimos MD‏ @aftimosp 6:36 AM - 2 Apr 12 via Twitter for iPad • Tweet
  • Abnormality impedes therapy. Normalizing blood & lymphatic vasculature, matrix, & restoring NO gradient results in > survival benefit. #AACR. -- Carole Tactacan‏ @carole12 7:03 AM - 2 Apr 12 via Tweetbot for iOS • Tweet
  • Bob Kerbel: Based on selection of oral #AACRabstracts this yr, myeloid cells seem to be "high-profile" area of angiogenesis research-- Al Lalani‏ @Histidine57 1:38 PM - 1 Apr 12 via Twitter for iPad • Tweet

Microenvironment
  • Microenvironment determines differences in tumor vasculature depending on tumor site of origin #AACR. -- Philippe Aftimos MD‏ @aftimosp 6:28 AM - 2 Apr 12 via Twitter for iPad • Tweet
  • Normalizing the tumor microenvironment for better therapeutic efficacy #AACR. -- Philippe Aftimos MD‏ @aftimosp 6:24 AM - 2 Apr 12 via Twitter for iPad • Tweet
  • Interesting talk by Rakesh Jain at #AACR about how the tumor #microenvironment can be modified to enhance efficacy of #chemotherapy-- BMC Medicine‏ @BMCMedicine 11:35 AM - 2 Apr 12 via web • Tweet

TARGETING P53



  • DeBussche: p53 is mutated in half of cancers #aacr. -- Pieter Droppert‏ @3NT 2:45 PM - 1 Apr 12 via Echofon • Tweet 
  • Mutated but we still can not target. RT @3NT: DeBussche: p53 is mutated in half of cancers #aacr. -- Naoto T. Ueno 上野直人‏ @teamoncology 2:49 PM - 1 Apr 12 via YoruFukurou • Tweet 
  • DeBussche: discussing drugability challenge of the HDM2 pocket which binds p53 #aacr. -- Pieter Droppert‏ @3NT 2:49 PM - 1 Apr 12 via Echofon • Tweet 
  • DeBussche: restoring p53 function by targeting HDM2 - genetic drivers for response: HDM2 amplification #aacr. -- Pieter Droppert‏ @3NT 2:47 PM - 1 Apr 12 via Echofon • Tweet 
  • Next up In new drugs on horizon session: Laurent DeBussche from Sanofi on SAR299155 HDM2-p53 antagonist #aacr. -- Pieter Droppert‏ @3NT 2:40 PM - 1 Apr 12 via Echofon • Tweet 


TARGETING PI3K, ETC.
  • #Novartis has presented positive First-in-human phase I results of #BYL719 in 35 patients with advanced solid malignancies. Live from #AACR-- Cortellis Editorial‏ @Cortellis 1:57 PM - 1 Apr 12 via Twitter for BlackBerry® · Tweet 



  • 【#AACR 101】 BL719: #BYL719 is a oral PI3K inhibitor. By #Novartis-- Naoto T. Ueno 上野直人‏ @teamoncology 1:59 PM - 1 Apr 12 via YoruFukurou • Tweet 
  • Phase I BYL719 for advanced solid malignancy required PIK3 mutation. Dose-finding revealed max tolerated dose of 400mg Daily. #AACR. -- David Woessner‏ @pinfoto 1:31 PM - 1 Apr 12 via Echofon • Tweet 




  • BYL179[sic] trial expanding to 45 pts. following partial responses in 3 pts. at doses of >270mg qd. #AACR. -- David Woessner‏ @pinfoto 1:41 PM - 1 Apr 12 via Echofon · Tweet 


BYL719 by Novartis targets PI3K (read more at Novartis Oncology)





  • Interesting poster on PI3k signaling in neuroblastoma at #aacr from Susanne Fransson abstract #2237. -- Pieter Droppert‏ @3NT 1:14 PM - 2 Apr 12 via Camera on iOS Tweet
  • #Amgen has presented preclinical results of a new PI3K inhibitor, #AMG-511. Live from #AACR. -- Cortellis Editorial‏ @Cortellis8:12 PM - 1 Apr 12 via Twitter for BlackBerry®Tweet 
  • GSK's PI3K-beta inhibitor has potentially fewer side effects on mice (less hyperglycemia and hyperinsulinemia) #AACR. -- Philippe Aftimos MD‏ @aftimosp 12:02 PM - 1 Apr 12 via Twitter for iPad Tweet


  • A new compound from #Aerterna Zentaris#AEZS-136 has shown excellent in vivo antitumor efficacy results after oral administration at #AACR. -- Cortellis Editorial‏ @Cortellis 8:19 PM - 1 Apr 12 via Twitter for BlackBerry® · Tweet 

AEZS-136 is an orally active anticancer PI3K/Erk 1/2 inhibitor ; Aeterna Zentaris Inc. (AEZS, AEZ.TO)


OTHER NOVEL DRUGS IN DEVELOPMENT



  • #Nerviano's #NMS873 is the most potent and selective VCP inhibitor discovered so far with an IC50 of 30nM. Live from #AACR. -- Cortellis Editorial‏ @Cortellis 1:45 PM - 2 Apr 12 via Twitter for BlackBerry® · Tweet
  • New drugs on the horizon being discussed at #aacr include AZD3514 SAR299155 ABT-199 http://pic.twitter.com/atcEafd6. -- Pieter Droppert‏ @3NT powered by Photobucket 1:09 PM - 1 Apr 12 via Camera on iOS · Tweet 
  • Preclinical #AACR poster on dual ALK/EGFR inhibitor with T790M mutation today in Hall F, Abstract 1794, 8 am-noon. Come by! -- ARIAD Pharmaceutical‏ @ARIADPharm 4:01 AM - 2 Apr 12 via HootSuite · Tweet
  • $INFI presents preclinical data of saridegib. Presentation in the "Publications Archive" at http://www.infi.com. -- JarenM‏ @JarenM 2:52 PM - 1 Apr 12 via Twitter for iPhone · Tweet
  • ARIAD presents new preclinical data on Ponatinib and AP26113 at #AACR http://ow.ly/a1omk. -- ARIAD Pharmaceutical‏ @ARIADPharm 6:03 AM - 2 Apr 12 via HootSuite · Tweet



All prevention drugs discussed have some anti-inflammatory activity in combination or alone: Triterpenoids, rexinoids, SAHA. #AACR. -- David Woessner‏ @pinfoto 11:13 AM - 2 Apr 12 via Echofon Tweet




TACKLING RESISTANCE AND MANAGING STAGE IV DISEASE

  • AC: now focusing on drug resistance and combinatorial therapy (the latter is major theme of this meeting for sure" #AACR. -- Kenna Shaw‏ @wyattsgirl 12:04 PM - 2 Apr 12 via TweetDeck • Tweet
  • 【#AACR Editorial】Tumor heterogeneity becomes a big issue for drug resistance when the genetic driving force is not clear-- Naoto T. Ueno 上野直人‏ @teamoncology 6:30 AM - 2 Apr 12 via Twitterrific for Mac • Tweet
  • Coolest idea yet: genetic test to determine WHO will develop metastasis (even before a primary tumor presents)! #hopeful #AACR. -- Jamie Ledezma‏ @blakesmum 11:58 AM - 1 Apr 12 via Twitter for iPhoneTweet


  • Vogelstein: Doctors can circumvent resistance to therapy by treating tumors when they're as small as possible & using combo therapies #AACR. -- Cancer Minute‏ @CancerMinuteGW 2:11 PM - 2 Apr 12 via web • Tweet


  • #AACR: Ph. II trial shows low-dose IL-2 and 13-cis retinoic acid improves survival in patients with advanced cancers. -- J Nat'l Cancer Inst‏ @JNCI_Now 6:47 AM - 2 Apr 12 via web • Tweet
  • Maintenance Rx w/IL-2 and 13-cis retinoic acid an inexp method to increase survival in pts with stage 4? #AACR http://fb.me/W0DDVCGy . -- Naoto T. Ueno 上野直人‏ @teamoncology 2:24 PM - 2 Apr 12 via Facebook • Tweet
  • #AACR IL-2 immunotherapy and Chemotherapy Regimen May Prolong Survival in Advanced Cancershttp://bit.ly/HGWMos via @AACR. -- Scott Merville‏ @smerv 2:28 PM - 2 Apr 12 via Tweet Button • Tweet

CANCER MODELS


  • Zebrafish can host mouse brain tumors & still retain same histology & global transcriptome bio. Richard J. Gilbertson shows us how. #AACR. -- Carole Tactacan‏ @carole128:21 AM - 2 Apr 12 via Tweetbot for iOS • Tweet
  • Researchers show the creation of in vivo cell lineage tracers which help study motility and invasion of cancer cells #AACR. -- PKI Life Science‏ @PKILifeScience 1:22 PM - 1 Apr 12 via Mobile Web • Tweet
-- Twitter updates up to Apr 02


RELATED POSTS:

Postcard From the AACR 2012 Annual Meeting - Part 2 - funding, trials, epidemiology
Postcard From the AACR 2012 Annual Meeting - Part 3 - personalized medicine, NGS, TCGA
Postcard From the AACR 2012 Annual Meeting - Part 4 - The Grapevine, quotes, and interesting stuff
Breast Cancer Tweets From AACR 2012 Annual Meeting


No comments:

Post a Comment